Teva’s Austedo Positioned To Compete With A Generic Rival
Executive Summary
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.
You may also be interested in...
Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone
A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.
Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone
Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.
Roche's Neuroscience Franchise Gets Lift From Huntington's Breakthrough
Roche is aiming to bolster its future neuroscience franchise with another potential breakthrough product in neurology to add to its clinical-stage efforts in Alzheimer's disease, and its success in developing the first therapy for primary progressive multiple sclerosis, Ocrevus.